PL1888081T3 - Kompozycje zawierające PUFA i sposoby ich zastosowania - Google Patents

Kompozycje zawierające PUFA i sposoby ich zastosowania

Info

Publication number
PL1888081T3
PL1888081T3 PL06770862T PL06770862T PL1888081T3 PL 1888081 T3 PL1888081 T3 PL 1888081T3 PL 06770862 T PL06770862 T PL 06770862T PL 06770862 T PL06770862 T PL 06770862T PL 1888081 T3 PL1888081 T3 PL 1888081T3
Authority
PL
Poland
Prior art keywords
methods
compositions containing
containing pufa
pufa
compositions
Prior art date
Application number
PL06770862T
Other languages
English (en)
Polish (pl)
Inventor
Richard J. Wurtman
Ingrid Richardson
Original Assignee
Massachusetts Institute Of Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37452701&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL1888081(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Massachusetts Institute Of Technology filed Critical Massachusetts Institute Of Technology
Publication of PL1888081T3 publication Critical patent/PL1888081T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
    • A23L2/52—Adding ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Fertilizers (AREA)
  • Separation, Recovery Or Treatment Of Waste Materials Containing Plastics (AREA)
  • Carbon And Carbon Compounds (AREA)
PL06770862T 2005-05-23 2006-05-23 Kompozycje zawierające PUFA i sposoby ich zastosowania PL1888081T3 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US68335205P 2005-05-23 2005-05-23
US71607705P 2005-09-13 2005-09-13
US75505806P 2006-01-03 2006-01-03
US76175306P 2006-01-25 2006-01-25
EP06770862.8A EP1888081B1 (en) 2005-05-23 2006-05-23 Compositions containing pufa and methods of use thereof

Publications (1)

Publication Number Publication Date
PL1888081T3 true PL1888081T3 (pl) 2017-07-31

Family

ID=37452701

Family Applications (1)

Application Number Title Priority Date Filing Date
PL06770862T PL1888081T3 (pl) 2005-05-23 2006-05-23 Kompozycje zawierające PUFA i sposoby ich zastosowania

Country Status (15)

Country Link
US (3) US10086009B2 (enExample)
EP (3) EP3090740A1 (enExample)
JP (3) JP5566603B2 (enExample)
CN (1) CN105663151A (enExample)
AU (2) AU2006251569B2 (enExample)
BR (2) BRPI0613303A8 (enExample)
CA (2) CA2645645C (enExample)
DK (1) DK1888081T3 (enExample)
ES (2) ES2615521T3 (enExample)
HU (1) HUE031206T2 (enExample)
NZ (3) NZ600740A (enExample)
PL (1) PL1888081T3 (enExample)
PT (1) PT1888081T (enExample)
RU (1) RU2603470C2 (enExample)
WO (2) WO2006127620A2 (enExample)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070004670A1 (en) * 1998-07-31 2007-01-04 Richard Wurtman Compositions containing citicoline, and methods of use thereof
US8143234B2 (en) 1998-07-31 2012-03-27 Massachusetts Institute Of Technology Uridine administration improves phosphatide synthesis, synaptic transmission and cognitive function
US8518882B2 (en) * 1998-07-31 2013-08-27 Massachusetts Institute Of Technology Methods and compositions for ameliorating or inhibiting decline in memory or intelligence or improving same
US8314064B2 (en) 1998-07-31 2012-11-20 Massachusetts Institute Of Technology Uridine administration stimulates membrane production
EP1572115B1 (en) * 2002-11-27 2015-01-21 Ampio Pharmaceuticals, Inc. Treatment of diseases and conditions mediated by increased phosphorylation
PT1888081T (pt) * 2005-05-23 2017-03-01 Massachusetts Inst Technology Composições contendo pufa e seus métodos de utilização
MX336435B (es) * 2005-07-08 2016-01-19 Dsm Ip Assets Bv Acidos grasos poliinsaturados para el tratamiento de demencia y condiciones relacionadas con pre-demencia.
EP1951308B1 (de) * 2005-11-25 2013-02-20 Gisela Susilo Kombinationspräparate enthaltend physiologische zellmembran-bestandteile, einschliesslich phosphatidylserin, cholin und ein pyrimidinnukleos/tid
CN101636167B (zh) * 2006-12-28 2012-10-03 株式会社明治 含有乳来源的磷脂的婴幼儿脑发育促进剂以及含有该促进剂的食品组合物
NZ582329A (en) * 2007-06-26 2012-09-28 Nutricia Nv Improving memory in subjects with mini-mental state examination of 24-26
WO2009002146A1 (en) 2007-06-26 2008-12-31 N.V. Nutricia Supporting activities of daily living
WO2009002145A1 (en) 2007-06-26 2008-12-31 N.V. Nutricia Lipid composition for improving function of brain functioning
WO2009002148A1 (en) * 2007-06-27 2008-12-31 N.V. Nutricia Food composition for prodromal dementia patients
US8343753B2 (en) 2007-11-01 2013-01-01 Wake Forest University School Of Medicine Compositions, methods, and kits for polyunsaturated fatty acids from microalgae
WO2009057994A1 (en) 2007-11-02 2009-05-07 N.V. Nutricia Unit dosage for brain health
WO2009059306A1 (en) * 2007-11-02 2009-05-07 Massachusetts Institute Of Technology Uridine dietary supplementation compliance methods and use thereof
PL2609812T3 (pl) 2007-12-20 2019-02-28 N.V. Nutricia Ciekły produkt zawierający nukleotydy/nukleozydy
WO2010088700A1 (en) * 2009-02-02 2010-08-05 Martek Biosciences Corporation Methods for improving cognitive function and decreasing heart rate
WO2011133580A1 (en) * 2010-04-19 2011-10-27 Back Bay Scientific Llc Use of drugs that activate p2y receptors to enhance synaptogenesis
WO2012125020A1 (en) 2011-03-14 2012-09-20 N.V. Nutricia Method for treating neurotrauma
JP2015501426A (ja) * 2011-10-21 2015-01-15 オムセラ・ファーマシューティカルズ・インコーポレイテッド 注意欠陥多動障害を処置するまたは予防する方法および組成物
WO2013066152A1 (en) * 2011-10-31 2013-05-10 N.V. Nutricia Method for improving executive function
BR112014020177A8 (pt) * 2012-03-02 2021-10-19 Nutricia Nv Uso de uma composição para a fabricação de um produto para diminuir, prevenir ou reverter a conectividade cerebral funcional prejudicada e/ou organização da rede cerebral prejudicada
WO2013129914A1 (en) * 2012-03-02 2013-09-06 N.V. Nutricia Method for improving functional synaptic connectivity
WO2014171813A1 (en) * 2013-04-17 2014-10-23 N.V. Nutricia Nutritional composition for improving brain function in phenylketonuria
CN103877144B (zh) * 2013-05-02 2017-02-22 杭州耐奇睿生物医药科技有限公司 花生衣活性组分的应用及包含该花生衣活性组分的组合物
WO2015138879A1 (en) * 2014-03-13 2015-09-17 Massachusetts Institute Of Technology Compositions containing pufa, uridine and choline and methods of use thereof
WO2016083362A1 (en) * 2014-11-25 2016-06-02 Fonden For Helene Elsass Centeret Composition for improving cognitive functions
WO2017069613A1 (en) 2015-10-23 2017-04-27 N.V. Nutricia Method for improving recognition and/or working memory in hyperphenylalanimenia and phenylketonuria patients
WO2017155387A1 (en) 2016-03-08 2017-09-14 N.V. Nutricia Method for supporting memory function and/or cognitive function
WO2017167415A1 (en) * 2016-03-30 2017-10-05 Nestec S.A. Compositions comprising fatty acids and their use
JP2019518798A (ja) * 2016-06-27 2019-07-04 オハイオ・ステイト・イノベーション・ファウンデーション リポヌクレオチドに基づくａｒｄｓの治療
EP3518919A1 (en) * 2016-09-29 2019-08-07 Société des Produits Nestlé S.A. Omega 3 fatty acids and choline as neuroprotectant in patients with no dementia
US20210077446A1 (en) * 2016-12-13 2021-03-18 Dsm Ip Assets B.V. Pufa salt formulations (ii)
WO2021231566A1 (en) * 2020-05-12 2021-11-18 Massachusetts Institute Of Technology The use of choline supplementation as therapy for apoe4-related disorders
EP4190319A4 (en) 2020-07-29 2024-05-01 Novamedica Limited Liability Company PHARMACEUTICAL COMPOSITION CONTAINING MEMANTINE AND CITICOLINE
WO2022258873A1 (es) * 2021-06-09 2022-12-15 Hospital Sant Joan De Deu Combinación nutracéutica y su uso para el tratamiento de trastornos neurológicos
CN113577092B (zh) * 2021-07-30 2022-07-01 陈玉松 一种延缓衰老的含核苷酸的组合物及其制备方法和应用
CN115774059A (zh) * 2021-09-07 2023-03-10 中国科学院深圳先进技术研究院 一种阿尔兹海默症生物标志物及其筛选方法和应用
TR2021016704A2 (tr) * 2021-10-26 2021-11-22 Bursa Uludag Ueniversitesi Üri̇di̇ni̇n ön uyaran aracili i̇nhi̇bi̇syon bozukluğu i̇le seyreden hastaliklarin tedavi̇si̇nde kullanimi
WO2023150389A1 (en) * 2022-02-07 2023-08-10 Cornell University Compositions and methods for increasing dha availability
CN115334384B (zh) 2022-08-05 2025-03-14 立臻科技(昆山)有限公司 一种移动终端会议音箱

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4221784A (en) * 1979-04-05 1980-09-09 Massachusetts Institute Of Technology Process and composition for treating disorders by administering lecithin
GB8601915D0 (en) * 1986-01-27 1986-03-05 Efamol Ltd Pharmaceutical compositions
US5198468A (en) * 1987-06-24 1993-03-30 Efamol Holdings Plc Essential fatty acid composition
US5470838A (en) 1987-10-28 1995-11-28 Pro-Neuron, Inc. Method of delivering exogenous uridine or cytidine using acylated uridine or cytidine
JP2524217B2 (ja) * 1988-04-18 1996-08-14 マルハ株式会社 脳機能改善組成物、学習能力増強剤、記憶力増強剤、痴呆予防剤または痴呆治療剤
CA2596241C (en) * 1993-06-09 2011-04-19 Martek Biosciences Corporation Methods and pharmaceutical compositions useful for treating neurological disorders
US20050027004A1 (en) 1993-06-09 2005-02-03 Martek Biosciences Corporation Methods of treating senile dementia and Alzheimer's diseases using docosahexaenoic acid and arachidonic acid compositions
US5492899A (en) * 1994-01-10 1996-02-20 Abbott Laboratories Infant nutritional formula with ribo-nucleotides
JPH07143862A (ja) 1994-05-06 1995-06-06 Maruha Corp 脳機能改善効果を有する機能性食品。
EP0831805A1 (en) * 1995-06-07 1998-04-01 Martek Biosciences Corporation Methods for controlling highly unsaturated fatty acid content in various tissues
JPH0975000A (ja) * 1995-07-07 1997-03-25 Nisshin Oil Mills Ltd:The 母子栄養用油脂含有飲食物
US6200624B1 (en) 1996-01-26 2001-03-13 Abbott Laboratories Enteral formula or nutritional supplement containing arachidonic and docosahexaenoic acids
DE19608137A1 (de) * 1996-03-02 1997-09-04 Meyer Lucas Gmbh & Co Lipid-Zubereitungen für diätetische Zwecke
JP3627043B2 (ja) 1996-04-24 2005-03-09 明治乳業株式会社 ｎ−６系列／ｎ−３系列脂肪酸バランス 改善ヌクレオチド含有乳児用食品
DK0935667T3 (da) * 1996-07-23 2007-04-10 Nagase Chemtex Corp Fremgangsmåde til fremstilling af docosahexaensyre og docosapentaensyre
PL343902A1 (en) 1997-02-21 2001-09-10 Abbott Lab Methods of and compositions for reducing enteritis and colitis morbidity rate
US6080787A (en) 1997-02-21 2000-06-27 Abbott Laboratories Methods for reducing the incidence of necrotizing enterocolitis
JPH10327804A (ja) 1997-06-04 1998-12-15 Meiji Milk Prod Co Ltd 核酸関連物質、ｄｈａ、アラキドン酸及び コレステロール含有栄養組成物
JP3731983B2 (ja) * 1997-08-27 2006-01-05 明治製菓株式会社 痴呆犬の夜鳴き改善薬
JP3408958B2 (ja) * 1997-10-24 2003-05-19 旭化成株式会社 魚介類由来の有用物質を含む組成物およびその有用物質の製造方法
US5977174A (en) * 1997-11-26 1999-11-02 Neuromedica, Inc. Cholinergic compositions and uses thereof
US7413759B2 (en) 1998-05-21 2008-08-19 Beech-Nut Nutrition Corporation Method of enhancing cognitive ability in infant fed DHA containing baby-food compositions
US8518882B2 (en) * 1998-07-31 2013-08-27 Massachusetts Institute Of Technology Methods and compositions for ameliorating or inhibiting decline in memory or intelligence or improving same
DK2145627T3 (da) 1998-07-31 2014-07-21 Massachusetts Inst Technology Anvendelse af uridin i kombination med cholin til behandling af en humør-lidelse eller en følelsesmæssig lidelse.
US20070004670A1 (en) * 1998-07-31 2007-01-04 Richard Wurtman Compositions containing citicoline, and methods of use thereof
US20050203053A1 (en) † 1999-07-30 2005-09-15 Wurtman Richard J. Uridine administration improves phosphatide synthesis, synaptic transmission and cogntive function
US6472378B2 (en) * 1998-08-31 2002-10-29 Pro-Neuron, Inc. Compositions and methods for treatment of mitochondrial diseases
AU6384099A (en) 1998-08-31 2000-03-21 Proteotech, Inc. Blended compositions for treatment of alzheimer's disease and other amyloidoses
US6596302B2 (en) 2000-04-13 2003-07-22 Abbott Laboratories Infant formulas containing long-chain polyunsaturated fatty acids and uses thereof
US7226916B1 (en) * 2000-05-08 2007-06-05 N.V. Nutricia Preparation for the prevention and/or treatment of vascular disorders
CA2344564C (en) 2000-09-14 2008-07-22 General Electric Canada Inc. Graded electric field insulation system for dynamoelectric machine
US6964969B2 (en) * 2001-04-19 2005-11-15 Mccleary Edward Larry Composition and method for treating impaired or deteriorating neurological function
GB0111282D0 (en) 2001-05-09 2001-06-27 Laxdale Ltd Potentiation of therapeutic effects of fatty acids
JP2003048831A (ja) * 2001-08-02 2003-02-21 Suntory Ltd 脳機能の低下に起因する症状あるいは疾患の予防又は改善作用を有する組成物
US6541043B2 (en) 2001-08-28 2003-04-01 Dexgen Pharmaceuticals, Inc. Method and synergistic composition for treating attention deficit/hyperactivity disorder
EP1302196A1 (de) 2001-10-16 2003-04-16 Habinger, René, Ing. Mag. Intelligenzfördernde Zahncreme
NL1019368C2 (nl) * 2001-11-14 2003-05-20 Nutricia Nv Preparaat voor het verbeteren van receptorwerking.
US6677470B2 (en) 2001-11-20 2004-01-13 Natural Asa Functional acylglycerides
US20030114415A1 (en) * 2001-12-14 2003-06-19 Wurtman Richard J. Compositions and methods for treating and preventing memory impairment using citicoline
US20040048926A1 (en) 2002-03-15 2004-03-11 Hoffman Dennis Robert Use of docosahexaenoic acid and arachidonic acid to enhance the visual development of term infants breast-fed up to the age of six months
WO2004028529A1 (en) * 2002-09-24 2004-04-08 Suntory Limited Composition with effects of decline prevention, improvement or enhancement of normal responses of cognitive abilities of a healthy person
JP2004231585A (ja) 2002-12-05 2004-08-19 Fancl Corp 生体内ホモシステインレベル低減用および上昇抑制用組成物
CA2508995A1 (en) * 2002-12-20 2004-07-15 The Mclean Hospital Corporation Use of cytidine-, creatine-, and adenosine-containing compounds and adenosine-elevating compounds for normalizing sleep/wake cycle, treating a sleep disorder or improving cognitive function
CN1203867C (zh) 2003-03-11 2005-06-01 刘威 精制海狗油在制备防治老年痴呆药中的应用
US7867541B2 (en) 2003-04-14 2011-01-11 Mead Johnson Nutrition Company Compositions and methods of formulation for enteral formulas containing sialic acid
US7951410B2 (en) * 2003-04-14 2011-05-31 Mead Johnson Nutrition Company Enteral compositions containing caseinoglycomacropeptide having an enhanced concentration of sialic acid
EP1670324A1 (en) 2003-09-26 2006-06-21 Nestec S.A. Nutritional composition with unsaturated fatty acids and trace elements
US8921422B2 (en) 2003-10-01 2014-12-30 The Iams Company Methods and kits for enhancing ability to learn in a puppy or kitten
AU2004317087A1 (en) 2003-10-08 2005-09-22 The Mclean Hospital Corporation Methods of treating psychiatric, substance abuse, and other disorders using combinations containing omega-3 fatty acids
EP1634599A1 (en) 2004-08-20 2006-03-15 N.V. Nutricia Iimmune stimulatory infant nutrition
EP1656839A1 (en) 2004-11-11 2006-05-17 N.V. Nutricia Nutrition containing lipid blend
US20060247153A1 (en) 2005-04-29 2006-11-02 Mcmahon Robert J Method of improving learning and memory in mammals
PT1888081T (pt) * 2005-05-23 2017-03-01 Massachusetts Inst Technology Composições contendo pufa e seus métodos de utilização
US7829126B2 (en) 2005-10-26 2010-11-09 Abbott Laboratories Infant formulas containing docosahexaenoic acid and lutein

Also Published As

Publication number Publication date
JP5566603B2 (ja) 2014-08-06
CA2645647A1 (en) 2006-11-30
ES2615521T3 (es) 2017-06-07
EP1909801B1 (en) 2016-12-28
EP1909801A2 (en) 2008-04-16
CA2645645A1 (en) 2006-11-30
NZ563660A (en) 2012-11-30
PT1888081T (pt) 2017-03-01
US10736912B2 (en) 2020-08-11
NZ600740A (en) 2014-02-28
US10525071B2 (en) 2020-01-07
CA2645645C (en) 2015-07-14
NZ563659A (en) 2011-05-27
CN105663151A (zh) 2016-06-15
US10086009B2 (en) 2018-10-02
US20100099645A1 (en) 2010-04-22
JP2014133767A (ja) 2014-07-24
DK1888081T3 (en) 2017-02-27
ES2624702T3 (es) 2017-07-17
EP1888081B1 (en) 2016-12-28
JP2008545693A (ja) 2008-12-18
BRPI0613274A2 (pt) 2009-08-04
EP1888081A4 (en) 2012-12-05
JP5566604B2 (ja) 2014-08-06
EP3090740A1 (en) 2016-11-09
WO2006127627A3 (en) 2009-04-16
HUE031206T2 (en) 2017-06-28
AU2006251569A1 (en) 2006-11-30
EP1909801B2 (en) 2020-03-18
AU2006251562B2 (en) 2012-03-22
RU2011120440A (ru) 2012-11-27
JP2008542280A (ja) 2008-11-27
EP1909801A4 (en) 2012-12-05
US20190167705A1 (en) 2019-06-06
US20100022567A1 (en) 2010-01-28
JP5823564B2 (ja) 2015-11-25
WO2006127627A2 (en) 2006-11-30
RU2603470C2 (ru) 2016-11-27
WO2006127620A3 (en) 2009-05-07
AU2006251569B2 (en) 2012-06-21
EP1888081A2 (en) 2008-02-20
ES2624702T5 (es) 2020-12-11
BRPI0613303A2 (pt) 2009-08-04
AU2006251562A1 (en) 2006-11-30
CA2645647C (en) 2016-07-12
WO2006127620A2 (en) 2006-11-30
BRPI0613303A8 (pt) 2018-01-30

Similar Documents

Publication Publication Date Title
PL1888081T3 (pl) Kompozycje zawierające PUFA i sposoby ich zastosowania
HRP20182133T1 (hr) Pripravci koji sadrže azelastin i postupci njihove upotrebe
IL189795A0 (en) Isoindole-imide compounds and compositions comprising and methods of using the same
PL2335782T3 (pl) Zastosowanie kompozycji zawierającej HFCO-1233zd
IL197161A0 (en) Derivatives of 4-(n-azacycloalkyl)anilides and compositions containing the same
IL189602A0 (en) Indenoisoquinolinone analogs and methods of use thereof
PL1824566T3 (pl) Kompozycje doustne zawierające ekstrakt z rozmarynu i związane sposoby
AP2008004392A0 (en) Compositions providing tolerance to multiple herbicides and methods of use thereof
IL198626A (en) Preparations containing positive-1 microorganisms and methods for their use
ZA200700809B (en) Corrosion-inhibiting compositions and use thereof
IL185309A0 (en) Isoqunoline compounds and methods of use thereof
IL182943A0 (en) Ovr110 antibody compositions and methods of use
PL2069467T3 (pl) Kompozycje wydzielające i sposoby stosowania
IL182126A (en) Preparations containing and used in the history of 5-phenoxyalkoxypsoralen
ZA200805711B (en) Solid biocidal compositions and methods of using the same
ZA200801554B (en) Compositions providing tolerance to multiple herbicides and methods of use thereof
EP1765321A4 (en) ANTIMICROBIAL COMPOSITIONS AND METHOD OF USE THEREOF
IL186606A0 (en) Compositions and uses of amooranin compounds
EP1937075A4 (en) SYNERGIC COMPOSITION AND METHOD OF USE
ZA200705093B (en) Oral compositions containing extracts of rosmarinus and related methods
IL180195A0 (en) Aequorin-containing compositions and methods of using same
GB0520930D0 (en) Composition and method of use
EP2046109A4 (en) PHOTOSYNTHETIC ORGANISMS, COMPOSITIONS AND METHODS FOR GENERATING THESE ORGANISMS
GB0517168D0 (en) Composition and method of use
AU2005904711A0 (en) Compositions and methods of use thereof